Pepinemab

Recent Alzheimer’s and dementia research highlights include FDA approval of Alpha Cognition’s Zunveyl, failed phase 3 trials, legal issues for Cassava Sciences, and compassionate use of a new drug. CTAD conference data revealed anti-tau drugs' lack of efficacy, while Tiziana’s foralumab received FDA clearance for compassionate use. Eisai’s anti-tau drug E2814 showed potential in reducing biomarkers. Roche’s trontinemab and UCB’s beprenemab faced setbacks, and Athira’s Fosgonimeton failed in Phase 2/3. Gene therapy LX001 showed stabilization in amyloid levels and reduction in tau biomarkers. Symptomatic treatments like Zunveyl and Montelukast showed promise in managing memory symptoms.

CTAD 2024 in Madrid showcased updates on Alzheimer’s clinical research, including Eisai’s E2814, Nilotinib, Roche’s trontinemab, UCB’s beprenemab, Vaccinex’s pepinemab, intranasal insulin and empagliflozin, Cognition Therapeutics’ CT1812, Eli Lilly’s ceperognastat, high-dose DHA, Lexeo Therapeutics’ LX001, nabilone, dronabinol, and CBD, highlighting safety, tolerability, and potential efficacy in various stages of Alzheimer’s.

Vaccinex to present pepinemab efficacy and safety data at CTAD Conference, hypothesizing pepinemab's ability to block SEMA4D signaling and slow Alzheimer's progression, with focus on cognitive decline and biomarkers. Pepinemab also shown to preserve brain vasculature integrity.